Authors

Nancy E. Davidson, MD

Latest:

Dr. Davidson on the Future of HER2-Targeted Therapies in Breast Cancer

Nancy E. Davidson, MD, discusses the future of HER2-targeted therapies in breast cancer.

Nancy E. Kemeny, MD

Latest:

Hepatic Infusion Can Convert CRC Liver Metastases to Operable State

Overall, compelling response rates and rates of conversion to resection for patients with initially unresectable colorectal liver metastases treated with hepatic arterial infusion suggest consideration of earlier initiation of the technique in chemotherapy-naïve patients as well as its adoption in patients who have failed first-line systemic chemotherapy before proceeding to second- or third-line regimens.

Nancy Fell Hill, MPH

Latest:

The ABCs of IRBs: A Brief Overview

At some point in their careers, most oncologists will need to submit a research proposal to their hospital's Institutional Review Board. Too many physicians view the IRB process as an additional bureaucratic burden in their already overloaded daily schedules.

Nancy Gordon, MD

Latest:

Dr. Gordon on Immunotherapy Research in Osteosarcoma

Nancy Gordon, MD, a pediatric oncologist and research assistant at The University of Texas MD Anderson Cancer Center, discusses current immunotherapy research being conducted in the field of osteosarcoma.

Nancy L. Lewis, MD

Latest:

Dr. Nancy Lewis Discusses the Regorafenib CORRECT Trial

Nancy L. Lewis, MD, from the Thomas Jefferson University Hospitals, discusses the phase III CORRECT trial that examined the multitargeted tyrosine kinase inhibitor regorafenib.

Nancy Lee, MD

Latest:

Novel Approach Reduces Treatment Toxicities in Patients With HPV-Related Oropharyngeal Cancer

The incidence of mouth and throat cancer is on the rise due to transmission of the human papilloma virus, but physicians at Memorial Sloan Kettering Cancer Center have managed to significantly reduce the intensity of treatment and improve quality of life for these patients.

Nancy Lin, MD

Latest:

Evolving Treatment Landscape of HER2+ Metastatic Breast Cancer

Closing out their discussion on novel therapies for HER2+ metastatic breast cancer, experts share excitement for future clinical trials and strategies.

Nancy Tice, MD

Latest:

Communication Breakdown: Technology in the Exam Room

Technology and medicine are a wonderful combination, but not if the doctor hides behind it, a real concern in a world of EMRs and handheld medical devices.

Nancy U. Lin, MD

Latest:

Dr Lin on the Safety of T-DXd for HER2+ Breast Cancer With/Without Brain Metastases

Nancy U. Lin, MD, discusses the safety data from DESTINY-Breast12 with T-DXd for HER2+ advanced/metastatic breast cancer with or without brain metastases.

Nancy Y. Lee, MD

Latest:

Treatment Paradigms Are Shifting for Locally Advanced HPV-Positive Head and Neck Cancers

A personalized treatment paradigm based on hypoxia imaging is promising and may yield a successful, personalized de-escalation strategy for patients with HPV-associated oropharynx cancer.

Naomi B. Haas, MD

Latest:

Dr. Haas on the Role of PSMA in Prostate Cancer

Naomi B. Haas, MD, discusses the role of prostate-specific membrane antigen in prostate cancer.

Naomi Fujioka, MD

Latest:

Dr. Fujioka on Remaining Questions After the PACIFIC Trial in NSCLC

Naomi Fujioka, MD, discusses the questions that remain after the PACIFIC trial in stage III non–small cell lung cancer.

Naoto Tada Ueno, MD, PhD, FACP

Latest:

Dr. Ueno on Liquid Biopsy

Naoto Tada Ueno, MD, PhD, FACP, from The University of Texas MD Anderson Cancer Center, discusses the advantages of liquid biopsy to detect and monitor tumor growth.

Naoto Ueno, MD, PhD, FACP

Latest:

Dr. Ueno on Patient-Reported Outcomes With Trastuzumab Deruxtecan in HR+/HER2-Low Breast Cancer

Naoto T. Ueno, MD, PhD, FACP, discusses patient-reported outcomes with fam-trastuzumab deruxtecan-nxki (Enhertu) in hormone receptor (HR)–positive/HER2-low metastatic breast cancer.

Narendranath Epperla, MBBS, MS

Latest:

Dr. Epperla on the Implications of an FDA Approval for Ublituximab/Umbralisib in CLL

Narendranath Epperla, MD, MS, discusses the implications of a potential FDA approval for the combination of ublituximab and umbralisib for patients with chronic lymphocytic leukemia.

Narjust Duma, MD

Latest:

Dr. Duma on the Importance of Mitigating Racial Disparities in Lung Cancer Research

Narjust Duma, MD, discusses the importance of mitigating racial disparities in lung cancer research.

Nash Gabrail, MD

Latest:

The OCM Is Both Good and Questionable

The OCM program is a good start on a path that is as rough as it gets in our healthcare system that needs reform, which can't come from legislation such as Obamacare.

Nasser H. Hanna, MD

Latest:

Dr. Hanna on Challenges With Consolidation Immunotherapy in Lung Cancer

Nasser H. Hanna, MD, discusses challenges in consolation immunotherapy for patients with lung cancer.

Nasser Hanna, MD

Latest:

Dr. Hanna on Approaching Biomarker Testing in Lung Cancer

Nasser H. Hanna, MD, discusses his approach to biomarker testing in lung cancer.

Natalie Pompilio

Latest:

Understanding the Smoking Gun

For the past 3 decades, Carlos L. Arteaga, MD, has focused his research on drug-resistant breast cancers, seeking to identify the causes of resistance and proposing combination therapies to beat that resistance.